Novartis (NVS) said to weight selling ritalin, clozaril, exelon drugs - Bloomberg
- Powell says recent inflation data point to need to keep rates higher for longer
- United Airlines maintains forecast after Q1 results top Wall Street estimates
- Dollar edges down but still close to 5-1/2 month high, Fed, Middle East in focus
- Oil dips as demand worries outweigh Middle East supply risks
- Risk sentiment among fund managers highest since January 2022 - BofA
- GE HealthCare (GEHC) Announces Resignation of Jan Makela, CEO of Imaging
- Barnes & Noble Education (BNED) Enters Definitive Agreement with Immersion (IMMR)
- Under Armour Inc (UAA) Announces Departure of Chief People and Administrative Officer Tchernavia Rocker
- Interactive Brokers (IBKR) posts Q1 earnings beat, raises dividend
- Planet Fitness (PLNT) Appoints Colleen Keating as CEO
- After-hours movers: United Airlines, J.B. Hunt, and more
- Midday movers: Morgan Stanley, UnitedHealth rise; Tesla falls
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
- After-hours movers: Tesla, Gildan Activewear, Macatawa Bank, and more
- Midday movers: Goldman Sachs and Meta Platforms rise; Apple and Tesla fall
Roth Capital Reaffirms Aduro Biotech (ADRO) at 'Buy'; Says Partial Clinical Hold Lift No Surprise
November 21, 2016 10:01 AM ESTRoth Capital affirms Aduro Biotech (Nasdaq: ADRO) with a Buy rating and $20 price target after the company announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold placed on its clinical trials evaluating the LADD (live, attenuated double-deleted) immunotherapy platform, enabling patient enrollment to resume in all Aduro-sponsored clinical studies.
The firm... More
Novartis (NVS) Acquires Selexys Pharmaceuticals in ~$665M Deal
November 21, 2016 6:23 AM ESTNovartis (NYSE: NVS) announced it has acquired Selexys Pharmaceuticals Corporation, a company specializing in development of therapeutics in certain hematologic and inflammatory disorders. Novartis exercised its right to acquire Selexys following receipt of results of the SUSTAIN study, a Phase II trial evaluating the use of SelG1, an anti-P-selectin antibody, in the reduction of vaso-occlusive pain crises in patients with sickle cell disease (SCD). Results from the study will be presented during the Plenary Scientific Session at the 58thAmerican Society of Hematology (ASH) Annual Meeting on December 4, 2016, in San Diego, California.
"Sickle... More